Klaria Pharma Holding Year-End Report

Additions to the management team and structural changes to prepare for an increased focus on clinical development and out-licensing

FOURTH QUARTER (OCTOBER–DECEMBER)

∞ Net sales amounted to 0.2 MSEK (0.0 MSEK)

∞ R&D costs for the period amounted to 9.7 MSEK (7.2 MSEK)

∞ Profit after tax amounted to -5.3 MSEK (-8.1 MSEK)

∞ Earnings per share for the quarter amounted to -0.17 SEK (-0.26 SEK)

∞ Cash flow from operating activities amounted to -5.7 MSEK (-2.9 MSEK)

∞ Cash and cash equivalents on the balance day amounted to 2.9 MSEK (8,0 MSEK)

∞ Shareholder’s equity per December 31, 2019 amounted to 82.1 MSEK (94.7 MSEK)

THE PERIOD JANUARY–DECEMBER

∞ Net sales amounted to 4.2 MSEK (0.0 MSEK)

∞ R&D costs for the period amounted to 24.2 MSEK (22.6 MSEK)

∞ Profit after tax amounted to -22.5 MSEK (-27.3 MSEK)

∞ Earnings per share for the quarter amounted to -0.73 SEK (-0.89 SEK)

∞ Cash flow from operating activities amounted to -14.8 MSEK (-9.1 MSEK)

∞ Cash and cash equivalents on the balance day amounted to 2.9 MSEK (8.0 MSEK)

∞ Shareholder’s equity per December 31, 2019 amounted to 82.1 MSEK (94.7 MSEK)

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.